Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players芒鈧劉 financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst

Myocardial Ischemia Market Research Report Information by Type (Symptomatic and Asymptomatic), Treatment & Diagnosis (Diagnosis and Treatment), End User (Hospitals & Clinics, Diagnostic Centers and Ambulatory Surgery Centers) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2030

ID: MRFR/MED/4355-CR | 135 Pages | Author: Rahul Gotadki| August 2019

Myocardial Ischemia Market Overview

The Myocardial Ischemia Market is expected to reach USD 1186.12 Million by 2030 at 5.70% CAGR during the forecast period 2022-2030 Myocardial ischemia is a medical condition characterized by the insufficient blood flow to the heart muscle via coronary arteries, commonly resulting in chest pain.

Factors such as the high prevalence of coronary heart disease, rising incidence of diabetes, and lifestyle changes provide suitable backgrounds for the development of market growth. However, the high cost of therapeutic surgeries and side effects related to medications are projected to restrain the market growth during the forecast period.

Market Dynamics

Myocardial ischemia is a common occurrence and occurs with increased frequency in patients with diabetes due to cardiac autonomic dysfunction. According to a study published in the Endocrinology, Diabetes & Metabolism Case Reports journal in 2013, ~22% of the patients diagnosed with type 2 diabetes were estimated to suffer from Silent Myocardial Ischemia (SMI). Moreover, it is reported that the prevalence of diabetes has increased. This is illustrative by the fact sheet of the World Health Organization (WHO) published in 2017. According to it, the global prevalence of diabetes among individuals ages 18 years or more was about 8.5% in 2014. Thus, it is interpreted that the rising prevalence of diabetes provides a necessary driving force for the myocardial ischemia market to expand.

Myocardial Ischemia Market Size, by End User, 2017 (USD Million) 聽Myocardial Ischemia聽Market

聽Source: MRFR Analysis


The myocardial ischemia market has been segmented into type, treatment & diagnosis, and end user.聽By type, the market has been bifurcated into聽symptomatic and asymptomatic. Based on treatment & diagnosis, the market has been divided into diagnosis and treatment. Diagnosis segment has been further segregated into imaging and stress test. The treatment has been further divided into medications and surgery. By end-user, the market has been classified as hospitals & clinics, diagnostic centers, ambulatory surgery centers, and others. The hospitals and clinics accounted for a market value of聽USD 18,744.2 million in 2023.

Key Players

The prominent players in the myocardial ischemia聽market are聽Taxus Cardium (US), ViroMed Co. Ltd. (Republic of Korea聽), Edward Lifesciences (US), Daiichi Sankyo Company Limited (Japan), Boston Scientific Corporation (US), Merck KGaA (Germany), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services Inc. (US), Bayer AG (Germany), and AstraZeneca (UK).

Some of the key strategies followed by the players operating in the myocardial ischemia聽market were innovation, product development, acquisition, and expansion.

Asia-Pacific聽Myocardial Ischemia聽Market Share, by Country, 2017 (%)聽Myocardial Ischemia聽Market

Source: MRFR Analysis

Regional Analysis

The myocardial ischemia market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is estimated to dominate the brain ischemia ischemiamarket during the forecast period. Americas accounts for the largest regional market owing to the rising prevalence of diabetes, obesity, physical inactivity, and excessive alcohol use among the population. The European market for myocardial ischemia is expected to be the second-largest during the forecast period. The high growth rate is due to the high incidence rate of cardiovascular diseases in Europe. According to the European Cardiovascular Disease Statistics 2017, 45% of deaths in Europe is due to cardiovascular diseases (CVD).

Additionally, the companies operating in the market are mainly focusing on mergers and acquisition, which is expected to support market growth. Asia-Pacific is estimated to be the fastest-growing market due to the rising prevalence of diabetes. According to the Asian Diabetes Prevention Initiative, 60% of the world鈥檚 diabetic patient live in Asia. Such high incidences of diabetes that lead to silent myocardial ischemia are likely to fuel the market growth.

Moreover, in the Asia-Pacific region, China accounted for a market share of聽23.5% in 2017. However, the Middle East and Africa are expected to observe slow growth due to less exposure to healthcare services and stringent government rules and regulations.

Key Updates

  • In聽July 2016, Angionetics Inc., a subsidiary of聽Taxus Cardium, entered into an agreement with Huapont Life Sciences covering a聽USD 3,000,000 investment,聽to support the Generx Phase 3 clinical and commercialization development program.

  • In聽February 2018,聽Edwards Lifesciences Corporation received the CE Mark for its self-expanding CENTERA valve, thus enhancing its transcatheter heart valve therapy segment.

  • In聽August 2017,聽Boehringer Ingelheim Pharmaceuticals, Inc. received FDA approval for CyltezoTM (adalimumab-adbm).

Market Segmentation

Myocardial Ischemia Market, by Type

  • Symptomatic

  • Asymptomatic

Myocardial Ischemia Market, by Treatment & Diagnosis

  • Diagnosis

  • Treatment

Myocardial Ischemia Market, by End User

  • Hospitals & Clinics

  • Diagnostic Centres

  • Ambulatory Surgery Centres

Myocardial Ischemia Market, by Region

  • Americas

    • North America

      • US

      • Canada

    • Latin America

  • Europe

    • Western聽Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe

    • Eastern Europe

  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • Republic of Korea

    • Rest of Asia-Pacific

  • Middle East & Africa

    • United Arab Emirates

    • Saudi Arabia

    • Oman

    • Kuwait

    • Qatar

    • Rest of The Middle East & Africa

Available Additional Customizations

  • Regulatory scenario

Intended Audience

  • Medical device manufacturers and distributors

  • Government research organizations

  • Hospitals and clinics

  • Regulatory agencies

  • Pharmaceutical companies

Report Attribute/Metric Details
聽聽Market Size 聽聽2030: USD 1186.12 Million
聽聽CAGR 聽聽5.70% (2022-2030)
聽聽Base Year 聽聽2021
聽聽Forecast Period 聽聽2022-2030
聽聽Historical Data 聽聽2020
聽聽Forecast Units 聽聽Value (USD Million)
聽聽Report Coverage 聽聽Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
聽聽Segments Covered 聽聽Type, Treatment & Diagnosis, End User
聽聽Geographies Covered 聽聽North America, Europe, Asia-Pacific, and Rest of the World (RoW)
聽聽Key Vendors 聽聽Taxus Cardium (US), ViroMed Co. Ltd. (Republic of Korea ), Edward Lifesciences (US), Daiichi Sankyo Company Limited (Japan), Boston Scientific Corporation (US), Merck KGaA (Germany), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services Inc. (US), Bayer AG (Germany), and AstraZeneca (UK).
聽聽Key Market Opportunities 聽聽New product launches and R&D Amongst major key Players
聽聽Key Market Drivers 路聽 Rising prevalence of diabetes 路聽 The increasing cases of coronary artery disease and diabetes 路聽 Growing awareness related to heart conditions 路聽 Technological advancement in treatments 路聽 Rising numbers of hospitals and healthcare infrastructure

Frequently Asked Questions (FAQ) :

Myocardial ischemia market projected to grow at approximately 5.70% CAGR during the assessment period (2022-2030).

The valuation of the myocardial ischemia market is estimated to increase to USD 1186.12 Million by the end of 2030.

Increasing awareness about heart conditions, technological advancement in medical science, and rising numbers of hospitals & healthcare infrastructure, are major tailwinds pushing the growth of the global myocardial ischemia market.

North America holds the largest share in the myocardial ischemia market, followed by Europe and the Asia Pacific, respectively.

ViroMed Co. Ltd. (Korea), Johnson & Johnson Services Inc. (US), Boehringer Ingelheim International GmbH (Germany), Taxus Cardium (US), Bayer AG (Germany), Daiichi Sankyo Company Limited (Japan), AstraZeneca (UK), Edward Lifesciences (US), Boston Scientific Corporation (US), Novartis AG (Switzerland), and Merck KGaA (Germany), are some of the top players operating in the myocardial ischemia market.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Request Free Sample
Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
Ask for Customization